80 likes | 223 Views
HIV-1/HIV-2 COMBINATION SCREENING AND OUTCOMES OF FOLLOW UP William R. Oleszko, Ph.D. Associate Director, Public Health Laboratory Department of Health and Mental Hygiene New York City. HIV ANTIBODY TESTING – 2004 April 2004: Initiated use of new HIV antibody screening assay
E N D
HIV-1/HIV-2 COMBINATION SCREENING AND OUTCOMES OF FOLLOW UP William R. Oleszko, Ph.D. Associate Director, Public Health Laboratory Department of Health and Mental Hygiene New York City
HIV ANTIBODY TESTING – 2004 April 2004: Initiated use of new HIV antibody screening assay •BioRad’s HIV-1/HIV-2 Plus “O” EIA April – December 2004: 73,955 specimen submissions 96.5% NEGATIVE for antibody to HIV-1/HIV-2 3.3% POSITIVE for antibody to HIV-1 0.2% INCONCLUSIVE for antibody to HIV-1
CATEGORIES FOR SPECIAL STUDY • Atypical but reactive HIV-1 Western blot banding pattern • Inconclusive: pregnant or two HIV-1 inconclusives within one month • Area of birth = Africa/Asia • HIV-2 reactivity • AIDS symptoms and HIV antibody negative • Child of HIV positive mother • HIV Positive, no ART, undetectable viral load, declining CD4 • HIV positive, on ART, undetectable viral load, declining CD4 • OraQuick preliminary positive confirmatory result = inconclusive
ASSAYS PERFORMED ON SPECIAL STUDY SPECIMENS Current: • HIV-1/HIV-2 Multispot Rapid EIA • HIV V3 serotype • CD4/CD8 T-cell Enumeration • HIV-1 DNA PCR • HIV-2 DNA PCR • Viral load - HIV-1 RNA PCR & HIV-1 bDNA Future: • HIV Genotyping/Resistance Testing
Public Health Laboratory PHL: Sara T. Beatrice, Ph.D., Assistant Commissioner Retrovirology Laboratory: Amado Punsalang, Jr., Ph.D. Robert Pirillo – Community Coordinator Mona El-Fishawy - HIV Screening Lab Mohammad Younis – HIV Supplemental Testing Lab Ed Lee. Ph.D. – HIV PCR Lab Orlin Trochev, MD, Ph.D. – HIV Genotyping/Resistance Lab